Line 26, replace "." with ---;---.

Page 6, line 8, replace "form" with ---from---.

Page 7, line 13, replace "ration" with ---ratio---.

Page 11, line 23, replace "be" with ---by---

Page 12, line 15, after "opposite" insert ---of---.

IN THE CLAIMS:

Please cancel claims 1-14 without prejudice.

Please amend the following claims:

15. (Amended) A vaccine composition comprising: a [minimized] peptide, wherein when said peptide is minimized, the minimized peptide is capable of binding to a Class II MHC receptor DR1 and inhibiting the binding of HA residues 306-318, [according to claim 5;] and

an immunologically acceptable carrier.

16. (Amended) [A] The vaccine composition of claim 15, [comprising: a synthetic peptide] wherein an amino acid sequence of said peptide has been modified to form a synthetic peptide, wherein when said synthetic peptide is minimized, the minimized synthetic peptide has superior binding affinity for a Class II MHC receptor DR1 and inhibiting the binding of HA residues 306-318; [according to claim 6;]and

an immunologically acceptable carrier.

17. (Amended) [A] The vaccine composition of claim 15, [comprising: a synthetic peptide] wherein an amino acid sequence of said peptide has been modified to form a

synthetic peptide, wherein when said synthetic peptide is minimized, the minimized synthetic peptide has greater inhibition of HA residues 306-318 binding to a Class II MHC receptor DR1; [according to claim 7;] and

an immunologically acceptable carrier.

Please add the following claims:

--21. (New) The vaccine composition of claim 15, wherein said vaccine is against pathogenic microorganisms and neoplasms.

22. The vaccine composition of claim 21, wherein said vaccine is against Enterotoxogenic E. Coli.

23. (New) The vaccine composition of claim 16, wherein said vaccine composition comprises at least a portion of said synthetic peptide.

24. (New) The vaccine composition of claim 17, wherein said vaccine composition comprises at least a portion of said synthetic peptide.

25. (New) The vaccine composition of claim 15, wherein said immunologically acceptable carrier comprises incapsulating microspheres.

26. (New) The vaccine of claim 25, wherein said incapsulation microspheres comprise biodegradable bio-compatible poly (DL-lactide-co-glycolide) as a bulk matrix.

27. (New) The vaccine composition of claim 16, wherein said immunologically acceptable carrier comprises incapsulating microspheres.

28. (New) The vaccine compostion of claim 27, wherein said incapsulation microspheres comprise biodegradable bio-compatible poly (DL-lactide-co-glycolide) as a bulk matrix.

29. (New) The vaccine composition of claim 17, wherein said immunologically acceptable carrier comprises incapsulating microspheres.

30. (New) The vaccine composition of claim 29, wherein said incapsulation microspheres comprise biodegradable bio-compatible poly (DL-lactide-co-glycolide) as a bulk matrix.

31. (New) The vaccine composition of claim 15, wherein said peptide comprises CS3 having the amino acid sequence of SKNGTVTWAHETNNSA, Seq. ID No: 3.

32. (New) The vaccine of claim 15, wherein said peptide comprises CS6α7 having the amino acid sequence of IIYQIVDEKGKKK, Seq. ID No: 6.

33. (New) The vaccine of claim 16, wherein said peptide comprises CS6α6 having the amino acid sequence of DEYGLGRLVNTAD, Seq. ID No: 5.

34. (New) The vaccine of claim 16, wherein said peptide comprises CS6β5 having the amino acid sequence of GTYAGHLTVSFYS, Seq. ID No: 12.

35. (New) The vaccine of claim 16, wherein said peptide comprises CS6β4 having the amino acid sequence of GEYPNSGYSSGTY, Seq. ID No: 11.

36. (New)The vaccine of claim 15, wherein said peptide comprises CS6β3 having the amino acid sequence of TSYTFSAIYTGGE, Seq. ID No: 10.

37. (New) The vaccine of claim 15, wherein said peptide comprises CS6β2 having the amino acid sequence of QLYTVEMTIPAGV, Seq. ID No: 9.

38. (New) A peptide that is immunogenic against Enterotoxogenic E.Coli, wherein when said peptide is minimized, the minimized peptide is capable of binding to a Class II MHC receptor DR1 and inhibiting the binding of HA residues 306-318.

39. (New) The peptide of claim 38, wherein an amino acid sequence of said peptide has been modified to form a synthetic peptide, wherein when said synthetic peptide is minimized, the minimized synthetic peptide has superior binding affinity for a Class II MHC receptor DR1.

40. (New) The peptide of claim 38, wherein an amino acid sequence of said peptide has been modified to form a synthetic peptide, wherein when said synthetic peptide is minimized, the minimized synthetic peptide has greater inhibition of HA residues 306-318 binding to a Class II MHC receptor DR1.

41. (New) The peptide of claim 38, wherein said peptide comprises CS3 having the amino acid sequence of SKNGTVTWAHETNNSA, Seq. ID No: 3.

42. (New) The peptide of claim 38, wherein said peptide comprises CS6α7 having the amino acid sequence of IIYQIVDEKGKKK, Seq. ID No: 6.

43. (New) The vaccine of claim 39, wherein said peptide comprises CS6α6 having the amino acid sequence of DEYGLGRLVNTAD, Seq. ID No: 5.

44. (New) The vaccine of claim 39, wherein said peptide comprises CS6β5 having the amino acid sequence of GTYAGHLTVSFYS, Seq. ID No: 12.

45. (New) The vaccine of claim 39, wherein said peptide comprises CS6β4 having the amino acid sequence of GEYPNSGYSSGTY, Seq. ID No: 11.